# A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review

> **NCT06362031** · — · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06362031
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06-01
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362031, "A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06362031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*